Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

Inclusion Criteria

• •Adult subjects, ages 18-65
• •Chronic HCV infection, defined as having documented HCV infection (antibody or RNA positivity) at least 6 months prior to Baseline (Day 1) with HCV viremia at screening
• •Screening Knodell necroinflammatory score \>= 3 based on liver biopsy evaluation (as determined by local pathologist) conducted anytime during the 45-day screening period
• •ALT \> the upper limit of the normal range (ULN) but \< 10 X ULN at the screening visit
• •Previously failed pegylated interferon-based HCV therapy in combination with ribavirin therapy, or is unable to tolerate or has contraindications to receiving interferon or ribavirin therapy
• •BMI between 19 and 36 kg/m2 (inclusive)
• •Creatinine clearance \>= 70 mL/min
• •absolute neutrophil count \>= 1000/mm3
• •Hemoglobin \> 10 g/dL
• •Have no clinical or laboratory evidence of hepatic decompensation